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The therapeutic potential of glial cell line-derived neurotrophic factor (GDNF) for Parkinson’s disease is likely to depend on sustained
delivery of the appropriate amount to the target areas. Recombinant adeno-associated viral vectors (rAAVs) expressing GDNFmay be a
suitable delivery system for this purpose. The aimof this studywas to define a sustained level of GDNF that does not affect the function of
the normal dopamine (DA) neurons but does provide anatomical and behavioral protection against an intrastriatal 6-hydroxydopamine
(6-OHDA) lesion in the common marmoset. We found that unilateral intrastriatal injection of rAAV resulting in the expression of high
levels of GDNF (14 ng/mg of tissue) in the striatum induced a substantial bilateral increase in tyrosine hydroxylase protein levels and
activity as well as in DA turnover. Expression of low levels of GDNF (0.04 ng/mg of tissue), on the other hand, produced only minimal
effects on DA synthesis and only on the injected side. In addition, the low level of GDNF provided85% protection of the nigral DA
neurons and their projections to the striatum in the 6-OHDA-lesioned hemisphere. Furthermore, the anatomical protection was accom-
panied by a complete attenuation of sensorimotor neglect, head position bias, and amphetamine-induced rotation. We conclude that
when delivered continuously, a low level of GDNF in the striatum (approximately threefold above baseline) is sufficient to provide
optimal functional outcome.
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Introduction
Glial cell line-derived neurotrophic factor (GDNF) is a potential
treatment for Parkinson’s disease (PD), recently evaluated in
Phase I clinical trials. Gill et al. (2003) showed therapeutic effects
of continuous infusion of GDNF into the putamen, although in a
recent news release, Amgen (Thousand Oaks, CA) reported that
in a Phase II study, 34 patients with advanced PD who received
continuous infusion of GDNF into the putamen showed no clin-
ical improvement after 6 months of treatment, despite evidence
of altered brain function (http://www.amgen.com/news/viewPR.
jsp?id 585632). Nutt et al. (2003), usingmonthly intracerebro-
ventricular injections of GDNF, found no beneficial effects, and
Kordower et al. (1999) found significant side effects using this
procedure, although there was no evidence of penetration of
GDNF into the appropriate target areas. These studies demon-
strate that if GDNF is to have a clinical application, development
of methods for delivery of appropriate amounts of GDNF to
target areas is required.
Because PD is a progressive disorder, the long-term efficacy of
GDNF treatment depends on its prolonged delivery (Kirik et al.,
2004). Sustained delivery (measured at 3 weeks, 10 weeks, and 6
months after injection) has been obtained by direct intracerebral
injection of GDNF using recombinant lentiviral or adeno-
associated viral vectors (rAAVs) and has been evaluated in intact
and lesioned rodents (Choi-Lundberg et al., 1997; Mandel et al.,
1997; Deglon et al., 2000; Kirik et al., 2000a; Rosenblad et al.,
2000a; Georgievska et al., 2002, 2004) and in primates (Kordower
et al., 2000; Eslamboli et al., 2003b). These studies show at least
two distinct effects of GDNF on dopamine (DA) neurons. GDNF
has a pharmacological effect on neurotransmission in intact adult
DA neurons by, for example, increasing DA turnover and regu-
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lating expression of tyrosine hydroxylase (TH) (Kirik et al.,
2000a; Kordower et al., 2000; Rosenblad et al., 2003; Georgievska
et al., 2004). GDNF also induces regeneration and sprouting in
injuredDA neurons (Kirik et al., 2000a; Georgievska et al., 2002),
although the pharmacological effect can appear in the absence of
regeneration and sprouting (Kirik et al., 2000a; Georgievska et al.,
2004).
Here, we compared biochemical effects after rAAV-mediated
expression of either a high or a low level of GDNF on the intact
DA system in monkeys to define a level of continuous GDNF
expression that did not have substantial pharmacological effects
on normalDAneurons. GDNF expression at 0.04 ng/mg of tissue
did not affect normal DA neurotransmission, so an rAAV ex-
pressing this amount was used in a recently developed intrastri-
atal 6-hydroxydopamine (6-OHDA) lesion (LES)model of PD in
monkeys (Eslamboli et al., 2003a). This low level of GDNF ex-
pression in the striatum provided substantial protection of the
nigrostriatal DA system and functional recovery on a range of
behavioral measures.
Materials andMethods
Monkeys and experimental design. Experimental procedures were per-
formed in accordance with theUnited KingdomAnimals (Scientific Pro-
cedures) Act (1986). Thirty-one laboratory-bred adult commonmarmo-
sets (Callithrix jacchus), 12 females and 19 males, were used. The
monkeys weighed 321–431 g andwere 23–51months of age at the start of
the experiment.
For experiment 1, three groups ofmonkeyswere used to determine the
effects of sustained expression of a low or high level of GDNF on the
intact primate nigrostriatal dopamine system: (1) groupGDNF-low (n
5) received an rAAV expressing a low level of GDNF and green fluores-
cent protein (GFP); (2) group GDNF-high (n  4) received an rAAV
expressing a high level of GDNF only; (3) group GFP (n 4) received an
rAAV expressing GFP only. Twelve weeks after the vector surgery, the
monkeys were killed, and their brains were removed for biochemical
analysis.
In experiment 2, each monkey was assigned to one of three groups on
the basis of their preoperative behavioral scores: (1) group GDNF plus
LES (n 6) initially received the GDNF-low vector; (2) group GFP plus
LES (n 6) initially received theGFP vector and served as a lesion/vector
control. Eight weeks later, both groups received an intrastriatal 6-OHDA
lesion on the same side as the vector surgery; (3) group INTACT (n 6)
did not receive any vector or the 6-OHDA lesion. This group served as the
nonlesioned control for behavioral measurements. Monkeys in groups
GDNF plus LES, GFP plus LES, and INTACT were assessed behaviorally
before any surgery, 7 weeks after the vector surgery (i.e., just before the
6-OHDA lesion), and 2, 7, 12, and 17 weeks after the 6-OHDA surgery.
When behavioral testingwas complete, theGDNFplus LES andGFPplus
LES monkeys were perfused, and their brains were removed and exam-
ined histologically.
Recombinant AAV vector preparation. The three vectors (see supple-
mental Fig. 1, available at www.jneurosci.org as supplemental material)
were constructed and titered at the University of Florida Gene Therapy
Center Vector Core (Gainesville, FL) using the methods detailed previ-
ously (Conway et al., 1997; Zolotukhin et al., 1999; Xu et al., 2001). The
GFP vector consisted of a chicken -actin promoter (CBA), which is a
cytomegalovirus enhancer with a downstream chicken -actin/rabbit
-globin hybrid intron driving humanized enhanced GFP. The GDNF-
high vector had a chicken -actin promoter with a cytomegalovirus en-
hancer with a downstream chicken -actin/rabbit -globin hybrid in-
tron that drove the production of the transgene. This construct included
the woodchuck posttranslational regulatory element downstream of the
GDNF gene. TheGDNF-low vector consisted of the sameCBA promoter
with a deletion of 693 bp in the intron and an internal ribosomal entry
site between the GDNF and the GFP genes. The GDNF-low vector had a
final infectious titer of 4.4  1011 IU/ml, the GFP vector had a final
infectious titer of 1.2 1011 IU/ml, and the GDNF-high had a final titer
of 4.0  1011 IU/ml. Given the accuracy of the titering methods, these
vectors had essentially equal titers (Burger et al., 2004).
Wild-type AAV-2 virus is not associated with any known human dis-
ease,making it an excellent tool for gene therapy in the brain. In addition,
in the recombinant AAV-2 vectors used in this study, all the viral genome
except the inverted terminal repeats has been replacedwith the transgene
of interest. Thus, no viral proteins are expressed by the transduced cells,
making it very unlikely for any immune reaction to take place in the
injected monkeys. Furthermore, Peden et al. (2004) have recently used
the same vector construct and showed that the vector injection alone did
not provoke infiltration of blood cells or activation of astrocytes or mi-
croglial cells in the brain beyondwhat can be seenwith injection of sterile
saline solution.
Surgery. For all surgery, monkeys were anesthetized with 0.5 ml of
alphaxalone–alphadolone (Saffan; 12 mg/ml, i.m.; Schering-Plough,
WelwynGardenCity, UK). A supplementary dose of 0.2–0.3ml of Saffan
was given during surgery, if necessary. After each surgery, the monkeys
were given an analgesic (Finadyne; 0.1 mg/kg, s.c.; Schering-Plough An-
imal Health, Mildenhall, UK).
In experiments 1 and 2, the vectors were injected unilaterally into the
striatum. The injections were made with a 28 gauge 10 l Hamilton
needle at a rate of 0.7 l/min. Six injections of 2 l (i.e., a total of 12 l)
were made in the striatum. After each injection, the needle was kept in
place for an additional 3 min before being withdrawn. The injections
were made using coordinates derived from the stereotaxic atlas of
Stephan et al. (1980) at the following sites: (1) anteroposterior (AP) 6.0,
lateral (LAT) 6.9, ventral (V) 10.0; (2) AP8.0, LAT6.2, V9.5; (3) AP8.0,
LAT2.8, V11.7; (4) AP10.0, LAT5.3, V9.4; (5) AP10.0, LAT2.4, V11.4; (6)
AP12.0, LAT3.0, V10.5.
In experiment 2, the monkeys in group GDNF plus LES and group
GFP plus LES underwent the intrastriatal 6-OHDA surgery 8 weeks after
the vector surgery. In a previous study, we found that nine intrastriatal
injections of 8 g each of 6-OHDA resulted in behavioral deficits that
recovered by 10weeks after lesion (Eslamboli et al., 2003a). In the hope of
achieving longer-lasting behavioral deficits, twice as many injections
were made into the striatum between coordinates AP6.5 to AP13.5,
LAT2.3 to LAT6.7, and V8.5 to V13.2 (i.e., a total of 18 injections of 8g
each of 6-OHDA). The injections were made ipsilateral to the vector
injections. 6-OHDA HCl (4 mg/ml free base weight dissolved in 0.01%
ascorbate/saline) was freshly prepared and stored on ice immediately
before use. Injections of 2 l each were made using a 28 gauge 10 l
Hamilton syringe at a rate of 0.5 l/min. After each injection, the needle
was left in place for 2 min before withdrawal.
Biochemical tissue analysis for experiment 1. For biochemical analysis,
the monkeys were premedicated with 0.05 ml of ketamine (Vetalar; 100
mg/ml, i.m.; Shering-Plough), killed with 0.6 ml of sodium pentobarbi-
tone (200 mg/ml, i.p.), and the brains were removed immediately after
death. Viewed from above, the corpus callosum was bisected, and the
cerebral hemispheres were rolled apart to expose the caudate and puta-
men, which were removed by blunt dissection, and each was chopped
and separated into three equal parts. To dissect the substantia nigra (SN;
pars compacta and pars reticulata), the cerebral peduncles were identi-
fied on the ventral surface of the brainstem, and the appropriate area
dorsal to these landmarks was removed by blunt dissection. All samples
were weighed, placed immediately on dry ice, and subsequently stored at
70°C until analyzed. The SN sample and one of the caudate and puta-
men samples from each side of each monkey were processed for deter-
mination ofGDNF levels using anELISA,whereas the remaining samples
were used for HPLC, Western blots, and TH activity measurements.
For GDNF ELISA, samples were sonicated in a homogenization buffer
(50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 10 g/ml aprop-
tinin, 1.7g/ml phenylmethylsulfonyl fluoride, 1.0g/ml leupeptin, 1.0
g/ml pepstatin) at a tissue concentration of 30 mg/ml and were centri-
fuged at 20,000 g for 10 min at 4°C. GDNF protein levels were deter-
mined on homogenates using an ELISA kit (G7621; Promega, Madison,
WI) according to the manufacturers recommendations, as used previ-
ously in rodent studies (Georgievska et al., 2004).
TH enzyme activity was determined according to Reinhard et al.
(1986). Striatal tissue was sonicated in 10 l/mg of homogenization
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buffer (20 mMMES, pH 6.1, 0.2% Triton) and centrifuged at 20,000 g
for 10 min at 4°C. The supernatant was collected and divided into two
parts; one was used for TH enzyme activity assay and the other forWest-
ern blot analysis (see below). A mixture of 4 l of L-[3,5- 3H]-tyrosine
(Amersham Biosciences, Little Chalfont, UK), 100 l of 500 M
L-tyrosine (Sigma, St. Louis, MO), 500 l of 200 mM MES, pH 6.1, 12 l
of catalase (12,690 U; Sigma), and 688 l of distilled H2O was prepared.
Ten microliters of the supernatant were added to 65 l of this mixture
together with 25 l of cofactor biopterin (0.6 mg/ml, dissolved in 3
mg/ml DTT; RBI, Natick, MA). Samples were then incubated for 20 min
at 37°C. The reaction was stopped with 1.0 ml of charcoal HCl, and the
samples were then centrifuged at 20,000  g for 15 min. One hundred
microliters of supernatant were added to 5 ml of scintillation liquid
(Instagel Plus; Packard Bioscience, Groningen, The Netherlands). TH
activity was expressed as the number of counts per minute per micro-
gram of protein (1214 Rackbeta; LKB-Wallac, Gaithersburg, MD). Pro-
tein concentrationwas determinedusing the Bradfordmethod (Bio-Rad,
Hercules, CA).
TH protein levels were determined using Western blot analysis, as
described previously (Georgievska et al., 2004). Homogenates were di-
luted 1:1 with Laemmli solution buffer (Bio-Rad) containing 2.5%mer-
captoethanol (Sigma) andwere frozen. Fourmicrograms of protein from
each sample were heated at 95–100°C for 5 min and then centrifuged
before being loaded onto a 4–20% SDS-PAGE gel (Criterion precast gel;
Bio-Rad) and run for 2 h at 150 V. The gels were electroblotted onto a
polyvinylidene difluoride membrane (Bio-Rad) and run for 2 h at 50 V.
Themembrane was probed with a primary antibody against TH (1:1000;
Pel-Freez, Rogers, AR) overnight. The membrane was then incubated in
anti-rabbit horseradish peroxide-linked secondary antibody (Amersham
Biosciences) and then in hyperfilm ECL solution (Amersham Bio-
sciences) for 1 min. The membrane was then exposed to ECL film, and
the film was developed. For each animal, the intact and the injected sides
were run on the same blots in duplicate. The density of each band was
measured using ImageJ software version 1.32 (a public domain product
distributed by the National Institutes of Health, Bethesda, MD; http://
rsb.info.nih.gov/ij/), and the data were expressed as percentage of un-
treated side.
Levels of DA and its metabolites 3,4-dihydroxyphenylacetic acid
(DOPAC) and homovanillic acid (HVA)were determined using reverse-
phase HPLC (Lotharius et al., 2002). The tissues of each brain were
homogenized in 1 ml of 0.1N perchloric acid, and after centrifugation at
14,000 g for 30 min, 200 l of the supernatant was filtered through a
0.22mglass filter. Ten or 20l of the filtered supernatantwas examined
for DA and its metabolites. For the HPLC, a YMCaqua C18 column (3
100 mm; particle size, 5 m) was used (YMC Europe GmbH, Scherm-
beck, Germany). Detection was made using an ESA (Zoeterwoude, The
Netherlands) electrochemical detector set at a potential of 300mV versus
anAg/AgCl reference electrode. Themobile phasewas delivered by an LC
10 AD Shimadzu (Tokyo, Japan) HPLC pump at 0.5 ml/min and con-
tained 0.051 MNaH2PO4H2Owith 0.92mM octanesulphonic acid, 0.048
mM Na2EDTA, and 11% methanol, adjusted to pH 3.7 with 1 M phos-
phoric acid and was degassed using an on-line degasser. Data were ac-
quired using the Shimadzu (chromatographic CLASS LC-10) software
package.
Behavioral tests for experiment 2. The data were collected by an exper-
imenter (A.E.) who was unaware of the group identity of the vector-
treated monkeys. The tasks used were the two-tubes choice task and the
six-tubes search task (see Fig. 1 for details). Both these tasks assess spatial
neglect within the contralesional hemifield of the monkey’s peri-
personal sensorium, because the monkey is free to use either arm and to
orient itself in front of the apparatus. The two-tubes choice task assesses
ipsilesional bias bymeasuringwhich of a pair of adjacent tubes, presented
at different places in peri-personal space and both containing a reward, is
chosen. The six-tubes search task assesses ipsilesional bias by measuring
the time the monkey takes to find the single reward hidden in one of six
tubes presented in a horizontal array in front of the monkey. The two-
tube task measures pure choice behavior, whereas the six-tube task as-
sesses choice behavior and voluntary motor action including praxis, be-
cause it measures time to complete the task. Measures were also taken of
the monkeys’ head position bias and amphetamine-induced rotation
(see Fig. 1 for details).
Monkeys were also tested on the hill staircase task (Marshall et al.,
2002), in which the monkey is required to reach through vertical slots in
a Plexiglas screen to retrieve rewards that are placed on the steps of two
staircases that ascend toward the center of the device. The slots are posi-
tioned laterally so that the monkey has to reach with the left arm into its
left hemispace and the right arm into its right hemispace. Monkeys with
unilateral 6-OHDA lesions take longer to retrieve rewards using the con-
tralesional arm on the contralesional side (Milton et al., 2004). This task
is ameasure of total contralesional disability comprisingmotor disability
and sensory neglect.
Histology andmorphometric analysis for experiment 2.After completing
their last behavioral tests, the monkeys in groups GDNF plus LES and
GFP plus LES from experiment 2 were premedicated with 0.05 ml of
ketamine (Vetalar; 100 mg/ml, i.m.; Shering-Plough), deeply anesthe-
tized with 0.6ml of sodium pentobarbitone (200mg/ml, i.p.), and perfused
transcardially with 300 ml of 0.1 M PBS, pH 7.4, followed by 300 ml of 4%
paraformaldehyde in PBS. The brainswere removed andplaced in 4%para-
formaldehyde solution for 24 h, transferred to 30% sucrose in PBS for 4 d at
4°C, and then cut at 40musing a freezing stage microtome.
Immunohistochemistry was performed as described by Eslamboli et
al. (2003b). Sections were treated for 10 min with 10% methanol/3%
hydrogen peroxide in PBS and preincubated in the appropriate blocking
serum for 1 h. The sections were then incubated overnight at room
temperature in the primary antibody. The antibodies used were rabbit
anti-TH antibody (1:250; Pel-Freeze), rabbit anti-vesicular monoamine
transporter-2 (VMAT2) antibody (1:2000; Chemicon, Temecula, CA),
rabbit anti-GFP (1:20,000; Abcam, Cambridge, UK), and goat anti-
GDNF antibody (1:2000; R&DSystems,Minneapolis,MN). Appropriate
secondary antibodies (goat anti-rabbit and horse anti-goat; 1:200 dilu-
tion; Vector Laboratories, Burlingame, CA) directed against the species
in which the primary antibody was raised were used in all cases. Sections
were incubated for 1 h in a streptavidin–biotin–peroxidase kit (Vector
Laboratories). The reactionswere visualized using 3,3-diaminobenzidine
as a chromagen. Sections were mounted on 1% gelatin-coated micro-
scope slides, dehydrated in ascending alcohol concentrations, cleared in
xylene, and coverslipped using Depex mountant.
Unbiased stereological estimation of the total number of cells in the
SNwasmadeusing the optical fractionator for bothTH-immunoreactive
(TH-IR) and VMAT2-immunoreactive (VMAT2-IR) sections as de-
scribed previously (Eslamboli et al., 2003b). Typically, 9 or 10 sections,
which covered the entire SN, were sampled at 40 magnification for
both TH-IR and VMAT2-IR using the Computer Assisted Stereological
Toolbox system developed by Olympus (Danmark A/S; Ballerup, Den-
mark). The size of the counting frame was chosen so that 100–200 cells
wouldbecountedperSNfor each immunoreactivemeasure.The totalnum-
ber of cells was estimated by the optical fractionator formula (West, 1999).
Striatal TH-IR and VMAT2-IR fiber density in the caudate nucleus
and putamen was determined by optical densitometry readings mea-
sured using ImageJ software version 1.32. Images were captured from
nine rostro-caudal levels over the whole striatum (AP 13.5 to AP 5.5)
(Stephan et al., 1980) using a constant illumination table and a high-
resolution digital camera (ProgResC14; Jenoptik, Jena,Germany). Read-
ings were corrected for nonspecific background density, measured from
a completely denervated part of the striatum, and averaged across all
sections, as described previously (Kirik et al., 2000a).
Statistical analysis. Postlesion data were analyzed for within- and
between-group effects using a repeated-measures ANOVA. Prelesion
comparisons between groups as well as histological and biochemical data
were made using factorial ANOVAs. Where there were significant inter-
actions, post hoc comparisons were made using t tests with Bonferroni
corrections.
Results
Effects of high- versus low-level rAAV-mediated GDNF
delivery on intact nigrostriatal DA neurons (experiment 1)
The GDNF levels obtained using the GDNF-low vector were
0.040  0.002 (SEM) ng/mg of tissue in the injected striatum,
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which was threefold to fourfold higher than that found in the
contralateral striatum or the rAAV–GFP-injected animals. There
was no significant change in GDNF levels in the ipsilateral SN.
Using the GDNF-high vector, 13.8 2.5 (SEM) ng/mg of tissue
was detected in the injected striatum, which was 100-fold
higher than that found in the contralateral striatum and1000-
fold higher than that found in rAAV–GFP-injected animals. In
addition, a very high level of GDNF [6.9  2.1 (SEM) ng/mg of
tissue] was also detected in the ipsilateral SN, and some increase
in the level of GDNFwas found in the contralateral SN (Table 1).
Expression of a high level of GDNF (GDNF-high group) pro-
duced a 6.8-fold increase in TH activity in the injected striatum
and a 2.5-fold increase in the uninjected striatum, comparedwith
levels found in the GFP group (Table 2). TH protein levels in the
injected striatum were 83% higher than in the uninjected stria-
tum, an elevation which matches the 85% increase in TH activity
in the injected compared with the uninjected striatum (although
the GDNF-high vector affected dopaminergic markers in both
hemispheres). Tissue DA content was significantly reduced (by
75% in the injected and 59% in the uninjected hemisphere),
whereas striatal HVA/DA and DOPAC/DA ratios were dramati-
cally increased in the injected (53- and 160-fold, respectively) and
uninjected (34- and 100-fold, respectively) hemispheres in the
GDNF-high group, suggesting that the very high turnover of DA
in the GDNF-high group had reduced the tissue levels of DA.
In contrast, expression of low levels of GDNF produced a
smaller (42%) but significant increase in the striatal TH activity
of the injected side only. Aside from striatal TH activity, no other
DA metabolic parameters were altered in the GDNF-low group.
Behavioral effects of continuous expression of low levels of
striatal GDNF in the lesionedmonkeys (experiment 2)
Twoweeks after the 6-OHDA lesion, the GDNF plus LES and the
GFP plus LES groups demonstrated equivalent and substantial
behavioral deficits in comparison to the INTACT group onmea-
sures of sensorimotor neglect (two-tubes and six-tubes tasks),
head position bias, and amphetamine rotation. For the two-tubes
task, when the two tubes were located on the lesioned side of the
monkeys, both the lesioned groups preferentially chose the re-
ward from the tube which was further away (i.e., more ipsile-
sional), whereas INTACT monkeys preferred the closer, con-
tralesional tube (Fig. 1A). For the six-tubes task, both the
lesioned groups spent substantially longer than the INTACT
group finding the food reward when it was in the most contrale-
sional position (Fig. 1B). Both lesioned groups had an equivalent
and substantial ipsilesional head position bias, in contrast to
INTACT monkeys that did not show a side preference (Fig. 1C).
After amphetamine challenge, the lesioned groups rotated ipsile-
sionally over the 30min interval in contrast to INTACTmonkeys,
which did not rotate (Fig. 1D). On the hill staircase task, the
GDNF plus LES monkeys took 108 17 (SEM) seconds, and the
GFP plus LES monkeys took 148 15 (SEM) seconds to retrieve
all the rewards on the contralesional side using the contralesional
arm in comparison to INTACT monkeys that took only 44  6
(SEM) seconds ( p  0.05 for each lesion group relative to
INTACT).
Between 7 and 17weeks after 6-OHDA surgery, a difference in
the lesion-induced deficits between the GDNF plus LESmonkeys
and the GFP plus LES monkeys became apparent (Fig. 1). Seven
weeks after the lesion, the GDNF plus LES monkeys were less
impaired than the GFP plus LES monkeys on the two-tubes and
six-tubes tasks and on head position bias score. By week 17, re-
covery was complete in the GDNF plus LES monkeys on these
tasks, whereas the GFP plus LES monkeys remained impaired.
Similarly, the GDNF plus LESmonkeys showed substantial ame-
lioration of amphetamine-induced rotation, whereas the GFP
plus LES monkeys did not. On the hill staircase task, the GDNF
plus LES group recovered more quickly than the GFP plus LES
group, reaching normal levels by 7weeks after the lesion, whereas
the GFP plus LES group returned to normal levels by 12 weeks
(group by week interaction, F(6,45) 5.28; p 0.001; confirmed
by post hoc analysis).
On tasks requiring skilled performance (two-tubes, six-tubes,
and staircase tasks), the monkeys in the GFP plus LES group
showed some improvement over time. This was probably as a
result of practice, because this group showed less improvement
onmeasures of posture and activity (head bias and amphetamine
rotation). The GDNF plus LES group might also have improved
somewhat with practice, so the crucial indicator of the efficacy of
Table 1. GDNF protein levels (in nanograms per milligram of tissue) as measured by ELISA from striatum and SN, 12 weeks after vector injection in experiment 1
Striatum Substantia nigra
Uninjected side Injected side Uninjected side Injected side
GDNF-high 0.079 0.023 13.780 2.5** 0.074 0.013** 6.879 2.052**
GDNF-low 0.015 0.007 0.040 0.002*** 0.017 0.001 0.023 0.002
GFP 0.013 0.003 0.012 0.002 0.012 0.002 0.014 0.001
All values are SEM. Repeated-measures ANOVA on all three groups showed significant group area side interaction (F(2,10) 7.4; p 0.011). Post hoc comparisons were made with the GFP group in each area on each side using
t test with Bonferroni correction. **p 0.01; ***p 0.001.
Table 2. TH enzyme activity and levels of DA and its metabolites in the injected striatum, 12 weeks after vector injection in experiment 1
Uninjected side Injected side
GFP GDNF-low GDNF-high GFP GDNF-low GDNF-high
TH activity (counts/min/g) 2883 306 2906 277 10086 312*** 2715 240 3865 234* 18628 381***
DA (pmol/mg of tissue) 253.0 22.0 207.0 21.0 103.6 54.7* 253.0 2 237.0 15 64.2 10.5***
DOPAC (pmol/mg of tissue) 4.4 0.4 3.6 0.4 120.5 17.2*** 4.4 0.8 4.55 0.5 186.1 66.1*
HVA (pmol/mg of tissue) 21.6 1.2 19.9 1.9 236.5 63.8** 21.6 1.5 31.5 1.7 270.7 40.3***
DOPAC/DA 0.018 0.003 0.018 0.002 1.810 0.45*** 0.017 0.003 0.019 0.002 2.890 0.77**
HVA/DA 0.087 0.008 0.097 0.005 3.080 0.52*** 0.085 0.005 0.136 0.014 4.570 1.07***
All values are SEM. Repeated-measures ANOVAs across each biochemicalmarker showed a significant group effect in all cases, significant side effects for TH activity, DOPAC/DA, and HVA/DA, and a significant group side interaction for
TH activity, DOPAC/DA, and HVA/DA. Post hoc t test with Bonferroni corrections were performed to compare each GDNF group to the GFP group on the same side. *p 0.05; **p 0.01; ***p 0.001.
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the GDNF lies in the difference in performance between these
groups at each time point.
GDNF-induced neuroprotection and regenerative sprouting
in the injured nigrostriatal DA system (experiment 2)
Immunohistochemistry for TH on sections through the SN and
basal ganglia of GFP plus LES monkeys demonstrated that the
6-OHDA lesion resulted in a substantial but incomplete reduc-
tion (by 63%) in the number of TH-IR cells in the SN (Fig. 2,
Table 3) and a reduction inTH-IR fiber density in the caudate (by
54%) and putamen (by 50%) (Fig. 3, Table 3). GDNF gene deliv-
ery had a neuroprotective effect against the 6-OHDA lesion. In
the lesioned SN, the GDNF plus LES monkeys had only a 16%
reduction in TH-IR cells (Fig. 2, Table 3). Striatal TH-IR fiber
innervation was also protected in the GDNF plus LES group.
There was a smaller reduction in TH-IR fiber density in the
GDNF plus LES group (44% reduction in
caudate; 13% in putamen) compared with
the reduction in the GFP plus LES mon-
keys (Fig. 3, Table 3). These findings were
confirmed by immunohistochemistry for
VMAT2, an additional marker for DA
neurons (Table 3). Fiber density measures
in the unlesioned side of the GDNF plus
LESmonkeys were very similar to those in
the unlesioned side of the GFP plus LES
monkeys. The number of cells in the SN in
the unlesioned side of the GDNF plus LES
monkeys was slightly higher than in the
unlesioned side of the GFP plus LESmon-
keys. The mechanism for this is unclear.
Inspection of sections stained with TH re-
vealed the presence of sprouting from the
rescued DA neurons in the GDNF plus
LES monkeys, both at the level of SN (Fig.
2C) and in the globus pallidus (Fig. 3F, I)
Figure 4 shows GDNF-IR and GFP-IR
staining in basal ganglia in a typical mon-
key from group GDNF plus LES. Staining
was visible in the ipsilesional globus palli-
dus and ipsilesional subthalamic nucleus.
This distribution of staining was unex-
pected, and levels of GDNF had not been
measured in these areas in experiment 1.
This distribution was probably a result of
anterograde transport of the protein to
these regions and increased affinity for the
rAAV in these regions in contrast to the
striatum (Kirik et al., 2000a). No staining
was seen in the SN, ventral tegmental area,
or elsewhere, suggesting that the transport
of the GDNF was to a large extent antero-
grade but not retrograde or transynaptic.
Inspection of histology revealed that all
detectable injection sites were in the neo-
striatum. Although, as shown in Figure 4,
GDNF stainingwas robust in striatal effer-
ent structures, GDNF staining was detect-
able in the striatumbut only as very faintly
staining and sparsely distributed cell bod-
ies in the injected hemisphere in some
GDNF plus LES monkeys. This finding is
probably attributable to the transport and
secretion of GDNF combined with its known long half-life in
vivo. Thus, accumulation of GDNF in striatal efferent structures
allowed levels to be detectable via immunohistochemistry. In
support of this contention, striatal GDNF levels were elevated
above background as measured by ELISA from dissections that
excluded efferent anatomical sites.
Discussion
When GDNF was expressed at a level that was only threefold to
fourfold above baseline, there were minimal or no effects on
various biochemical measures of DA neurotransmission,
whereas expression of a higher level ofGNDF significantly altered
all DA markers bilaterally. Because the viral titers of the three
vectors were very similar, the elevated levels of GDNF (and the
changes in dopamine markers) in the contralateral hemisphere,
after injection of the high expression vector, are presumably at-
Figure 1. Behavioral measures. A, The two-tubes task. On each of 30 trials, each monkey was presented with two tubes that
werebothbaitedwith a food reward. The tubeswerepseudorandomlypresented to the front, left, or right of themonkey such that
there were 10 trials in each position. The monkey was allowed to remove the food reward from either of the two tubes. Monkeys
will usually choose the nearer,more central, tubewhen the pair of tubes is presented to their left or right andwill choose randomly
when the tubes are presented centrally. Monkeys with an ipsilesional bias differ from normal monkeys in that they choose the
ipsilesional tube of the pair, regardless of the position inwhich they are presented. This difference ismostmarkedwhen the tubes
are presented on the ipsilesional side, because unlesionedmonkeyswill choose the nearer tube, and lesionedmonkeyswill choose
the tube which is further away, as illustrated in A, which shows the number of pieces retrieved from the further tube. B, The
six-tubes task. On each of 30 trials, each monkey was presented with a horizontal array of six tubes, one of which contained food
reward. Each tubewas baited five times in a pseudorandomorder. The animalwas allowed30 s per trial to find the reward. Normal
monkeys take very slightly longer to find a reward in anouter tube comparedwith the time taken to find centrally located rewards.
Monkeys with unilateral 6-OHDA lesions take longer to find the reward in any tube but are particularly slow to find the reward
when it is in themost contralesional tube (Milton et al., 2004).B shows the time taken to find the reward in themost contralesional
tube. C, Head position bias. Eachmonkeywas observed for 180 s/d for 3 d. C shows the average number of seconds per day that the
monkeys had their heads turned ipsilesionallyminus contralesionally.D, Amphetamine rotation. Eachmonkeywas videotaped for
30min, starting 30min after injectionwith amphetamine (0.5mg/kg, i.m.; Sigma).D shows average number of ipsilesionalminus
contralesional 360° rotations. After 6-OHDA lesions, there were group by week interactions (two-tubes task, F(6,45) 6.04, p
0.001; six-tubes task, F(6,45) 10.50, p 0.001; head position bias, F(8,60) 3.676, p 0.01). Differences at each time point
were compared using Bonferroni corrected t tests. *p 0.05 compared with INTACT;p 0.05, GDNF plus LES compared with
GFPplus LES. # indicates that therewas a groupdifference in amphetamine rotation (F(2,15)5.21;p0.05). The groupbyweek
interaction approached significance (F(6,45) 2.14; p 0.07). The “blobs” on the heads in the diagrams indicate the side of the
lesion. The arrows point to the tubes for which data are shown. Error bars represent SEM.
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tributable to substantial spread of the
GDNF protein. In view of the potential for
deleterious effects of such widespread dis-
tribution of high levels of GDNF, we used
the low-expressing vector and showed
that, although it did not alter the function
of intact DA neurons, it could still protect
the nigrostriatal DA system from the toxic
insult of the intrastriatal 6-OHDA lesion
and that it was able to provide a clear ben-
efit in a range of spontaneous and drug-
induced behavioral tasks.
Neuroprotection of the substantia nigra
The ability of GDNF to protect TH-IR cell
bodies in the SN after a lesion has been
used as the primary outcome measure in
several experiments (Beck et al., 1995;
Sauer et al., 1995; Tomac et al., 1995;
Winkler et al., 1996; Lu and Hagg, 1997).
Repeated injections or infusions of human
recombinant GDNF protein were found
to be more potent than single bolus injec-
tions (Sauer et al., 1995; Lu and Hagg,
1997; Rosenblad et al., 2000b). Lu and
Hagg (1997) performed a dose–response
study using osmoticminipumps to deliver
GDNF continuously over 2 weeks and found that ED50 was 1
g/d, whereas maximum protection was achieved at a dose of 3
g/d. A similar level of protection was achieved by direct injec-
tion of viral vectors encoding the GDNF gene (Choi-Lundberg et
al., 1997; Mandel et al., 1997; Deglon et al., 2000; Kirik et al.,
2000a; Kordower et al., 2000; Georgievska et al., 2002), with ex-
pression levels in the 0.2–6.3 ng/mg tissue range (for review, see
Bjorklund et al., 2000). These findings suggested that a low level
of GDNF would be sufficient for significant neuroprotection
when it is delivered continuously by the transduced cells locally in
the brain. However, a dose–response study using viral vectors has
never been performed.
In a previous study, we delivered higher levels of GDNF to
both the SN and striatum (using the same vector batch as the
GDNF-high vector in experiment 1 of the present study), fol-
lowed by a 6-OHDAnigro-striatal bundle lesion (Eslamboli et al.,
2003b). This lesion is known to lead to a rapid and near-complete
destruction of the cell bodies in the SN and an anterograde de-
generation of the ascending fiber bundles. In that experiment,
despite widespread and high levels of expression, the protective
effects ofGDNFweremodest both in the cell bodies of the SN and
in the striatal fiber terminals (Eslamboli et al., 2003b). In con-
trast, in the present work, an intrastriatal lesion model was used
in which the DA cells of the SN underwent retrograde degenera-
tion, and we found that the GDNF-low vector, which had mini-
mal effects on DA neurotransmission, produced near-complete
protection of DA cells.
The state of the TH-IR fiber terminals determines the
functional outcome
Several experiments have shown that even when almost all nigral
DA neurons are rescued after a lesion-inducing procedure, mar-
ginal, or no, benefits in motor performance in GDNF-treated
animals are observed unless striatal fiber terminals are also pro-
tected; the best functional recovery is seen when there is promi-
nent TH-positive innervation in the striatum (Winkler et al.,
1996; Sullivan et al., 1998; Rosenblad et al., 1999; Kirik et al.,
2000a,b). Importantly, however, Georgievska et al. (2002) have
shown recently that functional recovery could be compromised
in lesioned animals when high levels of GDNF were delivered
using a lentiviral vector. They showed that GDNF-treated rats
may fail to improve behaviorally, despite both nigral DA neurons
and their striatal fiber terminals being preserved. At least two
mechanisms were identified as potential contributing factors to
this outcome: (1) downregulation of TH in preserved DA termi-
nals and (2) aberrant sprouting of TH-positive fibers in output
nuclei of the basal ganglia. In a follow-up study, Georgievska et al.
(2004) showed that the downregulation of THwas time and dose
dependent and appeared to be a compensatory response of nigral
DA neurons to an initial enhancement of DA function and the
continued presence of high levels of GDNF.
In the present study, we detected prominent fiber sprouting in
the globus pallidus and the SN pars reticulata, although compar-
ison between VMAT2- and TH-immunostained sections indi-
cated that there was no effect of the low level of GDNF on TH
expression. Because animals treated with low-expression vector
showed excellent behavioral recovery, fiber sprouting in GP and
SN does not block execution of normal motor behaviors, pro-
vided that the striatal DA terminals are preserved and TH expres-
sion is not affected. Nonetheless, accumulation of GDNF in the
globus pallidus, distant from the injection sites, emphasizes the
need for additional investigation before clinical application.
Two weeks after the 6-OHDA lesion, all monkeys were im-
paired on measures of sensorimotor neglect, body asymmetry,
and drug-induced rotation. From 7 weeks after the lesion, the
monkeys in group GDNF plus LES began to display a gradual but
eventually complete amelioration of all these deficits, whereas the
monkeys in group GFP plus LES continued to display deficits on
mostmeasures up to the end of the experiment, 17weeks after the
lesion. In the GDNF plus LES group, the timing of recovery was
similar for the different behavioral measures, suggesting that the
neural mechanisms underlying the behavioral recovery were
Figure 2. TH-IR staining of the SN (AP 4.5). A, Unlesioned SN. B, Lesioned SN in a monkey from group GFP plus LES showing
substantial reduction in staining. C, Lesioned SN in a monkey from group GDNF plus LES showing partial protection against the
6-OHDA lesion. D–F, High-power micrographs taken from A–C, respectively, at the locations indicted by the boxes. E shows
reduction in TH-IR fibers. F shows substantial protection of the TH-IR fibers in the SN that extend into the SN pars reticulata. SNpc,
SN pars compacta; SNpr, SN pars reticulata; VTA, ventral tegmental area; cp, cerebral peduncles. Scale bars: (in A) A–C, 1 mm; (in
D) D–F, 0.1 mm.
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similar between tasks. Behavioral defi-
cits in the GDNF plus LES group 2 weeks
after lesion may indicate 6-OHDA-
induced damage to the DA terminals,
which GDNF could not prevent, fol-
lowed by a regenerative sprouting in-
duced by GDNF. This mode of action
would fit data obtained in the rodent in-
trastriatal 6-OHDA lesion model (Kirik
et al., 2000a). Although the duration of
the study was limited to 17 weeks, the
implications for long-term efficacy are
encouraging, because by 17 weeks, the
GDNF plus LES group animals were be-
having normally, whereas the GFP plus
LES group remained significantly
impaired.
Pharmacological effects of GDNF on
intact DA neurons
The present study and previous work
(Kirik et al., 2000a; Kordower et al., 2000;
Georgievska et al., 2004) suggest that con-
tinuous GDNF delivery initially upregu-
lates DA production and turnover in both
rodents and primates. However, although
this effect is rapidly saturatedwith increas-
ing levels ofGDNF in the rodent leading to
downregulation [preventing behavioral
recovery in lesioned animals (Georgievska
et al., 2002)], TH enzyme levels remain
upregulated in monkeys even with the
high dose GDNF delivered in experiment
1 of the present study. It is unclear why
monkey and rat brains respond differently
to long-term GDNF delivery. Both the ro-
dent and primate studies have used hu-
man GDNF, and there may be differences
between the binding properties of human
Figure 3. TH-IR staining of the basal ganglia (AP10.0 and 7.5). A, D, Unlesioned basal ganglia. B, E, Lesioned basal ganglia in a
monkey from group GFP plus LES showing substantial but subtotal reduction in staining in caudate (Caud) and putamen (Put). C,
F, Lesioned basal ganglia in a monkey from group GDNF plus LES showing partial protection against the 6-OHDA lesion. The
caudate, putamen, and globus pallidus (GP) are delineated by lines. G–I, High-power micrographs taken from D–F, respectively,
at the locations indicated by the boxes. The arrowhead inB shows needle track. Scale bars: (inA,D)A–F, 1mm; (inG)G–I, 0.1mm.
VMAT2-IR pictures are not shown but look similar to the TH-IR figures.
Table 3. Histological markers of effects of lesions and vector treatments in experiment 2
Unlesioned side Lesioned side
GFP plus LES
(n 6)
GDNF plus LES
(n 6)
GFP plus LES
(n 6)
GDNF plus LES
(n 6)
Cell counts
Substantia nigra
TH-IR 50,348 5495 61,424 4476 18,765 1222 51,839 4701***
(37%) (84%)
VMAT2-IR 48,247 2679 60,268 3893* 13,023 1611 50,565 3590***
(27%) (84%)
Fiber density (optical density units)
Caudate
TH-IR 35.5 2.7 36.8 1.2 16.2 2.0 21.3 3.0
(46%) (56%)
VMAT2-IR 39.5 4.4 38.5 2.5 16.7 1.7 19.3 2.9
(42%) (50%)
Putamen
TH-IR 35.7 1.2 35.0 2.0 17.7 1.3 30.5 2.5***
(50%) (87%)
VMAT2-IR 36.7 5.0 35.8 3.5 18.5 1.0 28.0 3.7*
(50%) (78%)
All values are SEM. Values in parentheses are lesioned side as percentage of unlesioned side in the same group. Separate ANOVAs over the TH-IR and VMAT2-IR cell counts showed significant group side interactions in both cases. Post
hoc t test showed that the GDNF plus LES group hadmuch higher cell counts than the GFP plus LES group on the lesioned side. Therewas a small increase in cell counts on the intact side in the GDNF plus LES group. Separate ANOVAs over the
TH-IR and VMAT2-IR fiber density showed significant group area side in both cases. Post hoc t test showed that the GDNF plus LES group had higher density measures than the GFP plus LES group in the putamen on the lesioned side.
*p 0.05; ***p 001.
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GDNF toprimate and rodent receptors and/or species differences
in the downstream events taking place within the activated DA
neurons.
Conclusions
Highly elevated levels of TH activity and DA turnover and re-
duced DA levels in both hemispheres (experiment 1 of this
study), together with the widespread distribution of GDNF to
nontarget areas after injection of the high-expression vector (Es-
lamboli et al., 2003b), may cause a concern for the safety of such
high levels of GDNF for patients, especially because high vector
expression had negative behavioral effects (e.g., contralateral
head positional bias) in intact animals (Eslamboli et al., 2003b).
The possibility of behavioral and cognitive side effects makes
external transgene regulation an absolute requirement for a
GDNF-based gene therapy in PD. On the other hand, it was im-
portant to know whether the lower level of GDNF expression,
which minimally affected DA function in normal animals, could
reverse lesion-induced anatomical and behavioral deficits. The
current data not only demonstrate that the lesioned DA system
can be rescued by low levels of GDNF but also highlight the
importance of regulating the levels of GDNF expression in pa-
tients, inwhich the administration of theminimumeffective level
of GDNF is the most desirable option.
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